EPI-STORM: Cytokine Storm in Organ Donors

NCT ID: NCT03786991

Last Updated: 2025-04-02

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

105 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-12-16

Study Completion Date

2025-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Kidney and liver transplantation are the treatment of choice and are often the last therapeutic option offered to patients with chronic renal and liver failure. More than 70% of kidneys and liver available for transplantation are obtained from donors following neurological death. Unfortunately, compared to living donation, transplant function, graft survival, and recipient survival are consistently inferior with kidneys and liver from neurologically deceased donors. This difference lies with the exacerbated pro-inflammatory state characteristic of deceased donors. Indeed, when neurologic death occurs, the immune system releases substances in the blood that could harm organs and particularly the liver and the kidneys. We believe that achieving a better understanding of the inflammatory processes of organ donors could be greatly informative to design future randomized controlled trial assessing the effect of personalized immunosuppressive therapy on organ donors to ultimately improve the care provided to donors so as to increase the number of organs available for transplantation and enhancing the survival of received grafts

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Severe neurological injuries, such as those observed in neurologically deceased donors, trigger a pro-inflammatory state that activates the immune system, increases vascular permeability, and recruits and activates immune cells in solid organs. The rapid and intense increase in circulating pro-inflammatory cytokines (e.g., IL-1, IL-6, TNF-α) following neurological death, has been referred to as the cytokine storm, one condition that is not seen among living donors. Interestingly, increased expression of TNF-α in the kidney and liver at the time of transplantation has been associated with reduced graft survival and acute rejection. Moreover, numerous studies have suggested that miRNA biomarkers can be targeted as diagnostic or therapeutic molecules in the field of organ transplantation. However, current models of graft injury fail to consider the epigenetic effects of physiological stressors that occurred in neurologically deceased donors. Although several biomarkers have been associated with graft dysfunction, the changes within the donor's inflammatory state, the mechanism underlying these events in donors, and the impacts on recipients are only poorly understood.

The investigators propose a multicenter prospective cohort study with the main objective of assessing the pro-inflammatory status of neurologically deceased donors by examining both miRNAs and circulatory cytokines and investigating its association with graft function in the recipient. Blood specimens will be collected at various time points in neurologically deceased liver and kidney donors in 5 organ recovery centres. The investigators hypothesize that in donors, Peak plasma concentration of pro-inflammatory cytokines and inflammatory-associated miRNAs targets (between consent and recovery) are associated with an increase in kidney delayed graft function and liver early graft dysfunction in the recipients. Considering that there is a therapeutic arsenal for treating donor cytokine storms( e.g., immunosuppressants) and that new targets based on a highly personalized mechanism could be developed we believe that the knowledge acquired in this research program will make it possible to improve the rate of livers and kidneys recovered from potential donors as well as enhance graft function in recipients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Organ Donation Liver Transplantation Kidney Transplantation Graft Dysfunction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Organ donors

Organ donors after neurologic death (NDD) of 18 years old and older for whom consent to organ donation has been obtained.

No intervention

Intervention Type OTHER

No intervention

Liver and kidney Recipients

Liver and kidney recipients of 18 years old and older.

No intervention

Intervention Type OTHER

No intervention

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

No intervention

No intervention

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patient admitted to the intensive care unit with a serious neurologic lesion
* Glasgow Coma Scale score ≤ 4
* Absence of sedation for the last 6 hours
* Age ≥ 18 years old


* Organ donor after neurologic death (DND) declaration as determined by the attending physician
* Consent to organ donation obtained

Exclusion Criteria

* S. aureus bacteremia
* Active neoplasia
* Receiving immunosuppressive therapy (including steroids) for \> 3 months

Specific to potential liver donors:

* Hepatic insufficiency defined as i) INR \> 1.5, ii) hepatic encephalopathy, iii) AST, ALT \> 2 times normal value

Specific to potential kidney donors:

* Polycystic kidney disease
* Chronic renal failure (i.e., eGFR \< 60 ml/min)

Phase 2 of the study:
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centre de recherche du CHUS

UNKNOWN

Sponsor Role collaborator

Université de Sherbrooke

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Dr Frédérick D'Aragon, MD FRCPC MSc

Role: PRINCIPAL_INVESTIGATOR

Université de Sherbrooke

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Hôpital Maisonneuve-Rosemont

Montreal, Quebec, Canada

Site Status RECRUITING

Centre Hospitalier Universitaire de Montréal

Montreal, Quebec, Canada

Site Status RECRUITING

Centre Hospitalier Universitaire de Québec- Université Laval

Québec, Quebec, Canada

Site Status RECRUITING

CIUSSS de l'Estrie-CHUS

Sherbrooke, Quebec, Canada

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Canada

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Marie-Hélène Masse, RRT, M.Sc.

Role: CONTACT

819-346-1110 ext. 14173

Daphnée Lamarche, PhD

Role: CONTACT

819-821-8000 ext. 70106

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Marie-Hélène Masse, RRT, MSc

Role: primary

819-346-1110 ext. 14173

Daphnée Lamarche, PhD

Role: backup

819-821-8000 ext. 70106

References

Explore related publications, articles, or registry entries linked to this study.

Clement AA, Lamarche D, Masse MH, Legare C, Tai LH, Fleury Deland L, Battista MC, Bouchard L, D'Aragon F. Time-course full profiling of circulating miRNAs in neurologically deceased organ donors: a proof of concept study to understand the onset of the cytokine storm. Epigenetics. 2022 Nov;17(11):1546-1561. doi: 10.1080/15592294.2022.2076048. Epub 2022 May 21.

Reference Type DERIVED
PMID: 35603508 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MP-31-2019-2960

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Kidney Transplant Failure
NCT01296061 TERMINATED